News

Birch pollen allergic rhinitis is the most common chronic disorder in the Northern part of the globe, and it attributes to significant morbidity and economic burden. According to a new study, pollen allergen immunotherapy has favorable effects on the molecular events and microbiome profile in the nasal membrane.

Updated, safer versions of diphtheria fusion toxin DAB-IL-2 show promise in reducing tumor growth.

Specialized lung cells appear in the developing fetus much earlier than scientists previously thought.

TB holds a special toxin-antitoxin system with spectacular action: once the toxin is activated, all bacterial cells die, stopping the disease. Researchers are investigating how to turn the bacteria on itself.

A combination of immune checkpoint blockade and targeted therapies that block normal DNA damage repair achieved significant tumor regression in mouse models of small cell lung cancer, suggesting a promising new approach for treating patients with this aggressive cancer.

BRAF-targeted therapies render resistant melanoma more sensitive to the attack of killer T cells. The findings pave the way in developing therapy for patients that have become resistant to BRAF inhibitors.

A combination of two drugs – one of them an immunotherapy agent – could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a Phase 3 clinical trial.

Stem cell technologies show promise for treating Parkinson's disease and may play an increasing role in alleviating at least the motor symptoms, if not others, in the decades to come.

Animal venoms are the subject of study at research center based at the Butantan Institute in São Paulo. But in this case, the idea is not to find antidotes, but rather to use the properties of the venoms themselves to identify molecular targets of diseases and, armed with that knowledge, develop new compounds that can be used as medicines.

A research team at the University of Louisville has discovered that an immune checkpoint molecule they developed for cancer immunotherapy, also protects against future development of multiple types of cancer when administered by itself.